Local delivery of antithrombotic drug prevents restenosis after balloon angioplasty in atherosclerotic rabbit artery

Japanese Circulation Journal

Volumn 60, Issue 12, 1996, Pages 981-992

  Tomaru, Takanobu ^a   Fujimori, Yoshiharu ^a   Morita, Toshihiro ^a   Aoki, Naoto ^b   Sakamoto, Yoshimitsu ^b   Nakamura, Fumitaka ^a   Omata, Masao ^a   Uchida, Yasumi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b Division of Pathology   (Japan)

Author keywords

Angioplasty; Antithrombin; Batroxobin; Local delivery; Restenosis

Indexed keywords

ARGATROBAN; BATROXOBIN; DALTEPARIN; HEPARIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CORONARY ARTERY ATHEROSCLEROSIS; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; FOLLOW UP; HEPARINIZATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; RABBIT; RECURRENCE RISK; RESTENOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOGRAPHY; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANGIOSCOPY; ANIMALS; ANTITHROMBINS; ARTERIOSCLEROSIS; BATROXOBIN; CONSTRICTION, PATHOLOGIC; FIBRINOLYTIC AGENTS; FLUORESCEIN-5-ISOTHIOCYANATE; HEPARIN, LOW-MOLECULAR-WEIGHT; ILIAC ARTERY; MALE; MICROSCOPY, CONFOCAL; PIPECOLIC ACIDS; RABBITS; THROMBOSIS;

EID: 0030454269     PISSN: 00471828     EISSN: None     Source Type: Journal    
DOI: 10.1253/jcj.60.981     Document Type: Article

References (40)

1. Ellis SG, Vandormael MG, Gowley MJ, DiSciascio G, Deligonul U, Topol EJ, et al: Multivessel Angioplasty Prognosis Study Group: Coronary morphological and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Circulation 1990; 82: 1193
2. Nobuyoshi M, Kimura T, Nosaka H, Mioka S, Ueno K, Yokoi H, et al: Restenosis after successful percutaneous transluminal coronary angioplasty: Serial angioplastic follow-up of 229 patients. J Am Coll Cardiol 1988; 12: 616-623
3. Block PC, Baughman KL, Pasternak RC, Fallon JT: Transluminal angioplasty: Correlation of morphologic and angiographic findings in an experimental model. Circulation 1980; 61: 778-785
4. Groves HM, Kinlough-Rathbone RL, Richardson M, Jorgensen L, Moore, S, Mustard JF: Thrombin generation and fibrin formation following injury to rabbit neointima. Studies of vessel wall reactivity and platelet survival. Lab Invest 1982; 46: 605-612
5. Steele PM, Chesebro JH, Stanson AW, Holmes DR Jr, Dewanjee MK, Badimon L, et al: Balloon angioplasty. Natural history of the pathophysiological response to injury in a pig model. Circ Res 1985; 57: 105-112
6. Wilentz JR, Sanborn TA, Haudenschild CC, Valeri CR, Ryan TJ, Faxon DP: Platelet accumulation in experimental angioplasty: time course and relation to vascular injury. Circulation 1987; 75: 636-642
7. 2. Blood 1981; 58: 198-205
8. Ross R, Masuda J, Raines EW, Gown AM, Katsuda S, Sasahara M, et al: Localization of PDGF-B protein in macrophages in all phases of atherogenesis. Science 1990; 248: 1009-1012
9. Ip JH, Fuster V, Israel D: The role of platelets, thrombin and hyperplasia in restenosis after coronary angioplasty. J Am Coll Cardiol 1991; 17: 77B-88B
10. Forrester J, Fishbein M, Helfant R: A paradigm of restenosis based on cell biology: clues for the development of new preventive therapies. J Am Coll Cardiol 1991; 17: 758-69
11. Willerson JT, Yao SK, McNatt J, Benedict CR, Anderson HV, Golino P, et al: Frequency and seventy of cyclic flow alterations and platelet aggregation predict the severity of neointimal proliferation following experimental coronary stenosis and endothelial injury. Proc Natl Acad Sci USA 1991; 88: 10624-628
12. Ellis SG, Roubin GS, Wilentz J, Douglas JS Jr, King SB III: Effect of 18- to 24 h heparin administration for prevention of restenosis after uncomplicated coronary angioplasty. Am Heart J 1989; 117: 777-782
13. Pepine CJ, Hirshfeld JW, Macdonald RG, Henderson MA, Bass TA, Goldberg S, et al: A controlled trial of corticosteroids to prevent restenosis after coronary angioplasty. Circulation 1990; 81: 1753-1761
14. Corcos T, David PR, Val PG, Renkin J, Dangiosse V, Rapold HG, et al: Failure of diltiazem to prevent restenosis after percutaneous transluminal coronary angioplasty. Am Heart J 1985; 109: 926-931
15. Reis GJ, Sipperly ME, McCabe CH, Sacs FM, Boucher TM, Silverman DI, et al: Randomized trial of fish oil for prevention of restenosis after coronary angioplasty. Lancet 1989; 2: 177-181
16. Wolinsky H, Thung S: Use of a perforated balloon catheter to deliver concentrated heparin into the wall of the normal canine artery. J Am Coll Cardiol 1990; 15: 475-481
17. Araki H, Muramoto J, Nishi K, Jougasaki M, Inoue M: Heparin adheres to the damaged arterial wall and inhibits its thrombogenicity. Circ Res 1992; 71: 577-584
18. Nunes GL, Hanson SR, King SB, Sahatjian RA, Barry JJ, Scott NA: Local heparin delivery with a hydrogel-coated PTCA balloon catheter inhibits platelet-dependent thrombosis. J Am Coll Cardiol 1993; 21: 117A
19. Azrin MA, Mitchel JF, Fram DB, Pedersen CA, Cartun RW, Barry JJ, et al: Decreased platelet deposition and smooth muscle cell proliferation after intramural heparin delivery with hydrogel-coated balloons. Circulation 1994; 90: 433-441
20. Tomaru T, Nakamura F, Fujimori Y, Omata M, Kawai S, Okada R, et al: Local treatment with antithrombotic drug can prevent thrombus formation: angioscopic and angiographic study. J Am Coll Cardiol 1995; 26: 1325-1332
21. Tomaru T, Uchida Y, Nakamura F, Sonoki H, Tsukamoto M, Sugimoto T: Enhancement of arterial thrombolysis with native tissue type plasminogen activator by pretreatment with heparin or batroxobin: an angioscopic study. Am Heart J 1989; 117: 275-281
22. Sherman CT, Litvack F, Grundfest W, Lee M, Hickey A, Chaux A, et al: Coronary angioscopy in patients with unstable angina pectoris. N Engl J Med 1986; 315: 913-921
23. Uchida Y, Tomaru T, Nakamura F, Sugimoto T, Furuse A, Fujimori Y, et al: Percutaneous coronary angioscopy in patients with ischemic heart disease. Am Heart J 1987; 114: 1216-1221
24. Ross R: The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801-809
25. Nabel EG, Yang Z, Liptay S, San H, Gordon H, Haudenschild CC, et al: Recombinant platelet-derived growth factor-B gene expression in porcine arteries induces intimal hyperplasia in vivo. J Clin Invest 1993; 91: 1822-1829
26. Okazaki H, Majesky MW, Harker LA, Schwartz SM: Regulation of platelet-derived growth factor ligand and receptor gene expression by α-thrombin in vascular smooth muscle cells. Circ Res 1992; 71: 1285-1293
27. Nikol S, Isner JM, Pickering JG, Kearney M, Leclerk G, Weir L: Expression of transforming growth factor-β1 is increased in human vascular restenosis lesions. J Clin Invest 1992; 90: 1582-1592
28. Lindner V, Reidy MA: Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against basic fibroblast growth factor. Proc Natl Acad Sci USA 1991; 88: 3739-3743
29. Clowes AW, Karnovsky MJ: Suppression by heparin of smooth muscle cell proliferation in injured arteries. Nature 1977; 265: 625-626
30. Rogers C, Karnovsky MJ, Edelman ER: Inhibition of experimental neointimal hyperplasia and thrombosis depends on the type of vascular injury and the site of drug administration. Circulation 1993; 88: 1215-1221
31. Haskel EJ, Prager NA, Sobel BE, Abendschein DR: Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion. Circulation 1991; 83: 1048-1056
32. Heras M, Chesebro JH, Penny WJ, Bailey KR, Badimon L, Fuster V: Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs. Circulation 1989; 79: 657-665
33. Dormandy JA, Reid HC: Controlled defibrination in the treatment of peripheral vascular disease. Angiology 1978; 29: 80-86
34. Holmer E, Mattson C, Nilsson S: Anticoagulant and antithrombotic effects of heparin and low molecular weight heparin fragments in rabbits. Thromb Res 1982; 25: 475-485
35. Hirsh J, Levine MN: Low molecular weight heparin. Blood 1992; 79: 1-17
36. Bara I, Billaud E, Gramond G: Comparative pharmacokinetics of low molecular weight (PK 10169) and unfractionated heparin after intravenous and subcutaneous administration. Thromb Res 1985; 39: 631-635
37. Beguin S, Lindhout T, Hemker HC: The mode of action of heparin in plasma. Thromb Haemost 1989; 60: 457-462
38. Mustard JF, Groves HM, Kinlough-Rathbone, Rackham MA: Thrombogenic and non-thrombogenic biological surfaces. Ann NY Acad Sci 1987; 516: 12-21
39. Tabata H, Mizuno K, Etsuda H, Miyamoto A, Isojima K, Satomura K, et al: The efficacy of argatroban in the prevention of reocclusion and restenosis after reperfusion therapy in patients with acute myocardial infarction. Circulation 1994; 90: 1-373
40. Serruys PW, Deckers JW, Close P and HELVETICA study group: A double blind randomized heparin controlled trial evaluating acute and long term efficacy of r-hirudin (CGP 39 393) in patients undergoing coronary angioplasty. Circulation 1994; 90: I-394